Skip to main content

Table 2 Adverse events with each DFPP modality

From: Novel double-filtration plasmapheresis preserves fibrinogen while removing immunoglobulin-G antibodies before ABO blood type-incompatible kidney transplantation

 

cDFPP (n = 23)

nDFPP (n = 12)

p value

Hypotension

0/23

0/12

n.s.#

Nausea and /or vomit

0/23

1/12 (8.3%)

n.s.#

Hemostasis prolongation of AVF after DFPP session

18/18 (100%)$

1/9 (11.1%)$

< 0.0001#

  1. #: chi-squared test, $: Hemostasis prolongation was defined as hemostasis of the AVF over 20 min in patients who had an AVF for hemodialysis, and the incidence was calculated in those who had an AVF for hemodialysis at the time of the DFPP session
  2. AVF Arteriovenous fistula, cDFPP conventional double-filtration plasmapheresis, nDFPP novel DFPP
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us